Literature DB >> 22411961

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.

L Grimaldi, F Barkhof, M Beelke, J Burton, T Holmoy, R Hupperts, J Killestein, P Rieckmann, M Schluep, J Smolders.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22411961     DOI： 10.1212/01.wnl.0000413180.13413.ce

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

1.  [Current immunotherapy of multiple sclerosis].

Authors:  F Paul; K Ruprecht
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

2.  Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials.

Authors:  Kira Hongell; Diego G Silva; Shannon Ritter; Daniela Piani Meier; Merja Soilu-Hänninen
Journal:  J Neurol       Date:  2017-12-14       Impact factor: 4.849

Review 3.  Vitamin D Actions on CD4(+) T Cells in Autoimmune Disease.

Authors:  Colleen Elizabeth Hayes; Shane L Hubler; Jerott R Moore; Lauren E Barta; Corinne E Praska; Faye E Nashold
Journal:  Front Immunol       Date:  2015-03-18       Impact factor: 7.561

4.  Can we prevent or treat multiple sclerosis by individualised vitamin D supply?

Authors:  Jan Dörr; Andrea Döring; Friedemann Paul
Journal:  EPMA J       Date:  2013-01-29       Impact factor: 6.543
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.